Stock Research: CSPC Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

CSPC Pharmaceutical

HKG:1093 HK1093012172
91
  • Value
    52
  • Growth
    87
  • Safety
    Safety
    80
  • Combined
    80
  • Sentiment
    76
  • 360° View
    360° View
    91
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock CSPC Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for CSPC Pharmaceutical. The consolidated Value Rank has an attractive rank of 52, which means that the share price of CSPC Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 52% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 87, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 80. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 76. ...read more

more
Index
Hang Seng
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
87 n/a n/a n/a
Safety
Safety
80 n/a n/a n/a
Sentiment
76 n/a n/a n/a
360° View
360° View
91 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
45 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
77 n/a n/a n/a
Sentiment
76 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
87 n/a n/a n/a
Safety Safety
80 n/a n/a n/a
Combined
80 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 n/a n/a n/a
Price vs. Earnings (P/E)
47 n/a n/a n/a
Price vs. Book (P/B)
36 n/a n/a n/a
Dividend Yield
93 n/a n/a n/a
Value
52 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
21 n/a n/a n/a
Profit Growth
100 n/a n/a n/a
Capital Growth
45 n/a n/a n/a
Stock Returns
97 n/a n/a n/a
Growth
87 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
85 n/a n/a n/a
Refinancing
43 n/a n/a n/a
Liquidity
88 n/a n/a n/a
Safety Safety
80 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to CSPC Pharmaceutical and broaden your portfolio horizons.

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

ICBC

SHH:601398
Country: China
Industry: Diversified Banks
Size: Large
Full Stock Analysis

China Automotive Systems

NAQ:CAAS
Country: China
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Orient Overseas (International)

HKG:316
Country: China
Industry: Marine
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: